BR112019017049A2 - formulações de canabinoides para o tratamento de acne - Google Patents

formulações de canabinoides para o tratamento de acne Download PDF

Info

Publication number
BR112019017049A2
BR112019017049A2 BR112019017049-9A BR112019017049A BR112019017049A2 BR 112019017049 A2 BR112019017049 A2 BR 112019017049A2 BR 112019017049 A BR112019017049 A BR 112019017049A BR 112019017049 A2 BR112019017049 A2 BR 112019017049A2
Authority
BR
Brazil
Prior art keywords
cbd
day
alcohol
pharmaceutical composition
skin
Prior art date
Application number
BR112019017049-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Cooper Eugene
callahan Matthew
Original Assignee
Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900493A external-priority patent/AU2017900493A0/en
Application filed by Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals, Inc. filed Critical Botanix Pharmaceuticals Ltd
Priority claimed from PCT/AU2018/050045 external-priority patent/WO2018148786A1/en
Publication of BR112019017049A2 publication Critical patent/BR112019017049A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
BR112019017049-9A 2017-02-15 2018-01-24 formulações de canabinoides para o tratamento de acne BR112019017049A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762459313P 2017-02-15 2017-02-15
AU2017900493A AU2017900493A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Acne
US62/459.313 2017-02-15
AU2017900493 2017-02-15
PCT/AU2018/050045 WO2018148786A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of acne

Publications (1)

Publication Number Publication Date
BR112019017049A2 true BR112019017049A2 (pt) 2020-04-14

Family

ID=67766784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019017049-9A BR112019017049A2 (pt) 2017-02-15 2018-01-24 formulações de canabinoides para o tratamento de acne

Country Status (9)

Country Link
US (1) US20220323401A1 (https=)
EP (1) EP3582770A4 (https=)
JP (2) JP2020508992A (https=)
CN (1) CN110769819A (https=)
AU (1) AU2018221881B2 (https=)
BR (1) BR112019017049A2 (https=)
CA (1) CA3053503C (https=)
IL (1) IL268728B2 (https=)
NZ (1) NZ756307A (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582770A4 (en) * 2017-02-15 2020-11-18 Botanix Pharmaceuticals Ltd CANNABINOID FORMULATIONS FOR THE TREATMENT OF ACNE
US12578326B2 (en) * 2020-02-25 2026-03-17 Advanced Animal Diagnostics, Inc. Methods and compositions for identifying a survivability index for an animal
CN114073687A (zh) * 2020-08-21 2022-02-22 四川大学华西医院 大麻二酚在制备防治玫瑰痤疮的药物中的用途
CN113372196B (zh) * 2021-07-02 2022-09-30 江南大学 8,9-二氢大麻二酚及其合成方法与应用
JP7736308B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736310B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736309B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機
JP7736306B2 (ja) * 2022-11-18 2025-09-09 株式会社ニューギン 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
DE60228713D1 (de) * 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2009072007A2 (en) * 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
MX2011011514A (es) * 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
PL2444081T3 (pl) * 2010-10-19 2015-09-30 Parenteral A S Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol
US8758826B2 (en) * 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
US8852648B2 (en) * 2012-11-06 2014-10-07 Rochal Industries, Llp Delivery of biologically-active agents using volatile, hydrophobic solvents
WO2014116653A1 (en) * 2013-01-22 2014-07-31 Coty Inc. Topical formulations and methods for the use thereof
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US20160374958A1 (en) * 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
EP3582770A4 (en) * 2017-02-15 2020-11-18 Botanix Pharmaceuticals Ltd CANNABINOID FORMULATIONS FOR THE TREATMENT OF ACNE
BR112019017018A2 (pt) * 2017-02-15 2020-04-14 Botanix Pharmaceuticals Ltd formulações de canabinoides para o tratamento de dermatite e doenças de pele inflamatórias

Also Published As

Publication number Publication date
IL268728B1 (en) 2024-05-01
IL268728A (en) 2019-10-31
EP3582770A4 (en) 2020-11-18
CA3053503A1 (en) 2018-08-23
CN110769819A (zh) 2020-02-07
US20220323401A1 (en) 2022-10-13
NZ756307A (en) 2023-01-27
CA3053503C (en) 2024-04-23
JP2020508992A (ja) 2020-03-26
EP3582770A1 (en) 2019-12-25
AU2018221881A1 (en) 2019-09-05
IL268728B2 (en) 2024-09-01
AU2018221881B2 (en) 2023-09-14
JP2022185150A (ja) 2022-12-13

Similar Documents

Publication Publication Date Title
BR112019017049A2 (pt) formulações de canabinoides para o tratamento de acne
CN110545807B (zh) 用于治疗皮炎和炎性皮肤病的大麻素制剂
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
BR112020014911A2 (pt) Regime de dosagem de canabinoide para dermatite e condições de pele inflamatórias
JP7561252B2 (ja) ざ瘡のためのカンナビノイド投薬レジメン
Salau et al. Enhancement of transdermal permeation of cannabinoids and their pharmacodynamic evaluation in rats
KR20130133295A (ko) 시클릭 뎁시펩티드를 포함하는 현탁액 유형 국소 제제
Bhaskar et al. A review on: ointment and ointment bases
Lein et al. Dermal
US20110294896A1 (en) Topical Treatment With Dapsone In G6PD-Deficient Patients
Pan et al. Oleogel-mediated topical administration of roflumilast and paclitaxel as a synergistic strategy to combat imiquimod-induced psoriasis
BR112019017011A2 (pt) formulações de canabinoides para o tratamento de psoríase
US20230025693A1 (en) Deep penetrating topical cannabinoid compositions and methods for treating musculoskeletal inflammation and pain
BR112019017045A2 (pt) composições para tratar acne

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICA??O DE DEVOLU??O DO PEDIDO EM FUN??O DA REVOGA??O DO ART. 229-C DA LEI N? 9.279, DE 1996, POR FOR?A DA LEI N? 14.195, DE 2021

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2654 DE 16-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.